Celcuity, Inc. (NASDAQ:CELC – Get Free Report) Director David Dalvey sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. Celcuity Stock Down 2.1%Shares of CELC traded down $2.41 during trading hours on Thursday, reaching $112.12. Deerfield Management Company L.P. bought a new stake in shares of Celcuity in the 3rd quarter worth approximately $36,236,000. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Check Out Our Latest Stock Report on CELCCelcuity Company Profile(Get Free Report)Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics.